# Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

> **NCT03580408** · PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 64 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Coexisting Medical Conditions

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Vinblastin

## Key facts

- **NCT ID:** NCT03580408
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-31
- **Primary completion:** 2021-02-19
- **Final completion:** 2021-08-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580408, "Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03580408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*